NCT04263766

Brief Summary

The study will use transcranial magnetic stimulation (TMS) to investigate the causal role of different brain regions during visual perception. TMS is a well-established technique used by hundreds of labs in the world. The risks associated with the technique are well understood and can be minimized by strict adherence to established safety guidelines. In the proposed study, the investigators will use TMS to specifically address the topic of how metacognitive evaluation is supported by the two prefrontal areas: the dorsolateral prefrontal cortex (DLPFC) and the anterior prefrontal cortex (aPFC). The data will be collected from healthy adults and will ultimately deepen the investigator's understanding of the mechanisms behind the normal processes related to confidence generation and metacognition.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
76

participants targeted

Target at P75+ for not_applicable healthy

Timeline
Completed

Started Feb 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 11, 2020

Completed
2 years until next milestone

Study Start

First participant enrolled

February 22, 2022

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2022

Completed
1 year until next milestone

Results Posted

Study results publicly available

September 15, 2023

Completed
Last Updated

September 15, 2023

Status Verified

August 1, 2023

Enrollment Period

6 months

First QC Date

February 7, 2020

Results QC Date

June 27, 2023

Last Update Submit

September 12, 2023

Conditions

Keywords

Transcranial Magnetic StimulationMetacognitionPrefrontal Cortex

Outcome Measures

Primary Outcomes (2)

  • Average Confidence Difference With the 0 ms Condition

    The average confidence difference for each delay condition and the 0 ms condition for each group (DLPFC or vertex). Confidence was self-reported together with the decision on a 4-point scale with the minimum score being one (not confident at all) and the highest score being four (very confident). The range of the scale is 1 (not confident at all) to 4 (very confident).

    6 months

  • Average Mratio Difference With the 0 ms Condition

    The average Mratio difference for each delay condition and the 0 ms condition for each group (DLPFC or vertex). The Mratio is derived from signal detection theoretical modeling of the observer's decision and confidence response. It is the ratio of two measures: the observer's metacognitive sensitivity (meta-d', the ability to discriminate between correct and incorrect responses) and the observer's stimulus sensitivity (d', the ability to discriminate between the two stimulus classes). The Mratio could be calculated from subjects' self-rated confidence together with task performance.

    6 month

Study Arms (1)

Healthy Adult Volunteers

EXPERIMENTAL

The experiment has a within-subject design where each subject will receive TMS to different brain areas. The analysis will involve comparing the effects of TMS to different regions.

Other: Transcranial magnetic stimulation

Interventions

TMS will be delivered to different brain areas in order to establish their contribution to visual metacognition.

Healthy Adult Volunteers

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • right-handed
  • adults 18-40
  • with normal or corrected-to-normal vision

You may not qualify if:

  • history of seizures
  • family history of epilepsy
  • stroke
  • severe headaches
  • metal anywhere in the head (excluding the mouth)
  • cardiac pacemakers
  • current use of medication for neurological or psychiatric conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Center for Advance Brain Imaging

Atlanta, Georgia, 30332, United States

Location

MeSH Terms

Interventions

Transcranial Magnetic Stimulation

Intervention Hierarchy (Ancestors)

Magnetic Field TherapyTherapeutics

Results Point of Contact

Title
Dr. Dobromir Rahnev
Organization
Georgia Institute of Technology

Study Officials

  • Dobromir A. Rahnev, Ph.D.

    Georgia Institute of Technology

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Model Details: TMS manipulation. Within-subjects design. Each participant will receive TMS to three different sites: DLPFC, aPFC, and a control site.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 7, 2020

First Posted

February 11, 2020

Study Start

February 22, 2022

Primary Completion

August 31, 2022

Study Completion

August 31, 2022

Last Updated

September 15, 2023

Results First Posted

September 15, 2023

Record last verified: 2023-08

Data Sharing

IPD Sharing
Will not share

Locations